chrisvoncsefalvay/vaers-outcomes huggingface dataset:
received the first dose of the vaccine on 30Dec2020 in a hospital. On 07Jan2021, he tested positive for COVID.; received the first dose of the vaccine on 30Dec2020 / On 07Jan2021, he tested positive for COVID / COVID symptoms; This is a spontaneous report from a contactable healthcare professional (patient) via a Pfizer-sponsored program. A 25-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection, lot number: EL1284, unknown lot number), intramuscular in left deltoid on 30Dec2020 at 19:30 at a single dose for COVID-19 immunisation/to prevent getting sick, to prevent the spread. Medical history and concomitant medication reported as none. The patient received the first dose of the vaccine on 30Dec2020 in a hospital. On 07Jan2021, he tested positive for COVID. His second dose is scheduled on 22Jan2021 and wants to know if he should get that or if there is any recommendation. The patient clarified that the COVID symptoms began on 06Jan2021. On the night of the 6th, he started to have chills and a headache throughout the night. He never had a fever or anything. He woke in the morning of 07Jan2021 kind of congested; runny nose, clear discharge. The patient wasn't able to taste his toothpaste, and then he couldn't smell his coffee. So, he experienced a loss of taste and smell. He was then tested for COVID (rapid test) on 07Jan2021 and tested positive. It was worse 2 days after he got sick. The patient progressively gotten better each day. The patient felt good today. He still can't taste or smell fully, some of it is coming back though. No additional vaccines administered on same date and no prior vaccinations within 4 weeks. The patient did not require a visit to emergency room/ physician office.  The patient underwent lab tests and procedures which included COVID Rapid test: positive on 07Jan2021. The patient was recovering from the events chills, headache, "congested- runny nose, clear discharge", and Loss of taste and smell, while unknown outcome for the remaining events. The patient would consider the seriousness as not significant.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product BNT162B2 to the reported drug ineffective and COVID-19 cannot be ruled out.
Pt has a rash with "bumps" in it over the left leg that the chicken pox vaccination was given. Vaccne given on 3/13/2017. Rash appeared on 3/21/2017, rash appears larger today than yesterday. RN instructed grandmother to go seek medical attention from PCP. She states they don't have one yet but she will take him to ED if it gets worse. Instructed her to put a line around it and watch the size of the area and she may use OTC Benadryl but to seek advise from pharmacist for dosage. Grandmother verbalized understanding of instructions.
Nauseous; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nauseous) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In June 2021, the patient experienced NAUSEA (Nauseous). At the time of the report, NAUSEA (Nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information were provided. No treatment information were given.
Within a minute of administering the vaccine. The patient fainted. She was conscious within a minute of fainting but was visibly confused. Her vital signs were normal and was able to speak and answer questions about her breathing and pain. EMT was on site within 5-10 mins of the incident and took her to the emergency room. She is currently home resting.
pt stated he noticed a foot long rash that developed on his back later in the day that he rcvd covid vax.  He took a picture and sent to his PCP.  He was instructed to have blood work done immediately.  He went next day for blood  work and is waiting on test results.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. No information regarding the patient's medical history or concurrent conditions was provided. On 07-JUN-2016, the patient was vaccinated with a dose of PROQUAD injection (dose, route of administration, lot# and expiry date were not reported) and with a dose of M-M-R II injection (dose, route of administration, lot# and expiry date were not reported). There were no concomitant therapies reported. No adverse symptoms were reported. There was no product quality complaint involved. Additional information has been requested.
no adverse effects reported; patient was vaccinated with improperly stored MMR II; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  On 03-JAN-2019, the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (albumin status rHA) one dose, lot # R019391 with expiration date 05-JUL-2020 (frequency, route and anatomical location were not provided) which was reconstituted with sterile diluent (dose, frequency, route, lot number and expiration date were not provided) for prophylaxis. No adverse effects reported.  The temperature and time frame were unknown by reporter. There was previously temperature excursions and digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011469: US-009507513-1907USA010301: US-009507513-1907USA010302: US-009507513-1907USA010303: US-009507513-1907USA010304: US-009507513-1907USA010305: US-009507513-1907USA010306: US-009507513-1907USA010307: US-009507513-1907USA010308: US-009507513-1907USA010309: US-009507513-1907USA010310: US-009507513-1907USA010311: US-009507513-1907USA010312: US-009507513-1907USA010313: US-009507513-1907USA010314: US-009507513-1907USA010315: US-009507513-1907USA010316: US-009507513-1907USA010317: US-009507513-1907USA010318: US-009507513-1907USA010319: US-009507513-1907USA010320: US-009507513-1907USA010321: US-009507513-1907USA010322: US-009507513-1907USA010323: US-009507513-1907USA010324: US-009507513-1907USA010325: US-009507513-1907USA010326: US-009507513-1907USA010327: US-009507513-1907USA010328: US-009507513-1907USA010329: US-009507513-1907USA010330: US-009507513-1907USA010331: US-009507513-1907USA010332: US-009507513-1907USA010333: US-009507513-1907USA010334: US-009507513-1907USA010335: US-009507513-1907USA010336: US-009507513-1907USA010337: US-009507513-1907USA010338: US-009507513-1907USA010340: US-009507513-1907USA010341: US-009507513-1907USA010342: US-009507513-1907USA010343: US-009507513-1907USA010344: US-009507513-1907USA010345: US-009507513-1907USA010346: US-009507513-1907USA010347: US-009507513-1907USA010348: US-009507513-1907USA010349: US-009507513-1907USA010350: US-009507513-1907USA010351: US-009507513-1907USA010352: US-009507513-1907USA010353: US-009507513-1907USA010354: US-009507513-1907USA010355: US-009507513-1907USA010356: US-009507513-1907USA010357: US-009507513-1907USA010358: US-009507513-1907USA010359: US-009507513-1907USA010360: US-009507513-1907USA010361: US-009507513-1907USA010362: US-009507513-1907USA010363: US-009507513-1907USA010364: US-009507513-1907USA010365: US-009507513-1907USA010366: US-009507513-1907USA010367: US-009507513-1907USA010368: US-009507513-1907USA010369: US-009507513-1907USA010370: US-009507513-1907USA010371: US-009507513-1907USA010372: US-009507513-1907USA010373:
Headache, Myalgia, weakness, fatigue Narrative:  Other Relevant History:
*Patient presented with acute upper extremity pain followed by weakness of left upper arm and mild symptoms in right arm. MD/orthopedist working diagnosis: brachial plexus neuritis. Treated with VOLTAREN & conservative measures. Patient continues to recover, experiencing upper extremity weakness & muscle loss. *Acute onset of pain was preceded by mild symptoms December 2010.
Interchange of vaccine products; Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 3 (booster), single (Lot number: FM9992), in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 02Nov2021 as dose 2, single (Lot number: 014F21A), in left arm and on 15Oct2022 as dose 4 (booster), single (Lot number: 053D22A), in left arm for covid-19 immunisation; COVID-19 vaccine nrvv ad26 (jnj 78436735) (COVID-19 VACCINE JANSSEN), on 11Apr2021 as dose 1, single (Lot number: 205A21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Probably sulfa drugs" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jan2023, outcome "not recovered" and all described as "Treatment of COVID-19"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "not recovered". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (01Feb2023) Negative, notes: tested negative or almost-negative; (03Feb2023) Positive, notes: Two days later, tested strongly positive and symptoms returned. Therapeutic measures were taken as a result of drug ineffective, COVID-19: the patient received Paxlovid from 25Jan2023 to 30Jan2023 (lot number 1923797A) for treatment of COVID-19: after taking the full course of Paxlovid, 5 days x 3 pills x2 per day, she tested negative or almost-negative. Two days later, she tested strongly positive, and symptoms returned.  No follow-up attempts are possible. No further information is expected.
No additional AE information; administered a properly stored but expired dose of GARDASIL 9; This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 13-FEB-2020, the patient was vaccinated with a properly stored, but expired dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # R022422, expiration date 25-NOV-2019 (exact dose and route of administration were not reported) for prophylaxis. No additional adverse event information.
This writer gave a Covid vaccine that was past the BUD date by one day. There were no adverse reactions.
24 hours after second shot had fever of 100.8 and chills.  I would consider mild symptoms which lasted about 6 hours.
Presented to ED and seen by Dr. who noted some of the following: History of Present Illness: complaints of shortness of breath, symptoms of COVID after vaccination on the 7th with manufacturer. Developed cough a couple days ago. Occasional fever. Poor taste for 4 days. Quit smoking 7 days ago. Known diabetic and elevated BP. No heart attack history and no chest pain now. Tested positive for COVID on July 27th, and tested positive again on 9/7/21. No symptoms either of those times, and testing was done due to exposure. COVID symptoms started on 9/19. Tested positive on admission.   RN note stated that patient was vaccinated on 8/27/21  Dr. was hospitalist who wrote noting:  Complaints of shortness of breath, female. Vaccinated in July with change of vaccine. Exposed earlier this month. Tested positive on 9/7/21. Complains now of SOB with cough, loss of taste and smell. Significantly decreased p.o. intake in the last 5 days. Denies any fever or chills. On arrival O2 SATs 87% on room air and was placed on 2L via nasal cannula, and says rose to 92%. Diagnoses: Pneumonia secondary to COVID-19 infection Acute hypoxic respiratory failure COPD with acute exacerbation Lactic acidosis Smoker 6-7/day Acute kidney injury Increased troponin
Information has been received from a consumer, who is a nurse, concerning her 15 month old male son with no medical history or allergies who on 09-SEP-2008 was vaccinated with the first dose of MMR II. There was no concomitant medication. On approximately 10-SEP-2008 (36 hours post-vaccination), the patient experienced redness in the face and hives that started on the back and spread all over the patient's body. The nurse applied BENADRYL topically and after 24 hours the rash went away. The patient did not seek medical attention. The outcome was reported as recovered/resolved. A product quality complaint was not involved. Additional information has been requested.
p/vax pt exp diarrhea, numbness of the vaccinated arm, weakness of the opposite arm, dizziness, h/a, nausea & a flare up of arthritis;it was reported that pt also treated for middle & inner ear infect;pt sought unspecified med attention;
Health care worker vaccination series for Moderna COVID Vaccine x 2 doses.   past medical history significant for hand eczema.   December 26th first dose of Moderna   Had a sore arm.  Second January 24th dose.   12 hours after shot   Temp on 1.304 body aches and chills for 24 hours and then was fine.   Then Feb 6th had the onset of  hives welts.   Went to the WIC and started on Hydroxyzine + prednisone.    Seen in allergy department on 2/17/2021 and treated with Hydroxyzine + prednisone taper for hives.  Had negative 25 OH Vitamin D leve, Allergy pediatric food panel, ASO,CRP IGE Thryoglolin antibody, thyroidperoxidase antibody and Vitamin B12  .   See in allergy on 3/12/2021 for flow up of chronic hives.  Noted linear streaks on upper chest and arms .  Treated with Ivermectin 5 mg now and then two weeks later for possible scabies.    3/29/2021 Hives are better.  But continues to be itchy and has linear red marks which is dermatographism .   The patient is not wheezing   She works at TEC in the surgery center.
Pt recvd vax 29AUG92 & 30AUG92 pt devel flu-like synd, joint pain, herpes labialis, round diffuse erythema & skin lesion consistent w/erythema multiforme;
received an expired dose; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 16-year-old female patient who received Men B NVS (Bexsero) (batch number ABXA92AZ, expiry date 28th February 2022) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 1st March 2022, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On 1st March 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient received an expired dose of Bexsero, which led to expired vaccine used. The reporter consented to follow up via email.
Information has been received from a consumer concerning her niece who on an unspecified date was vaccinated with a dose of MMR II. On an unspecified date, the patient was in a coma for a week after receiving MMR II. At the time of report, the patient's outcome was unknown. Upon internal review, a coma was determined to be an other important medical event. This is one of two reports received from the same source. No further information is available.
This spontaneous report was received from a physician refers to a currently 21 years old female patient. Pertinent medical history included leukemia but the patient was currently in remission. Drug reactions/allergies and concomitant medications were reported as none. Physician reporting that a patient received 3 doses of RECOMBIVAX HB, 5/0.5 mcrg/ml, vaccination, but currently has negative antibody titers. Doses were administered on 18-OCT-1994, 27-DEC-1994 and 14-NOV-1995. Each dose was given 0.5 ml intramuscularly. The physician also said that the patient received 2 doses of M-M-R II and the patient currently has antibody titers for measles and mumps. However, the patient currently did not have antibody titers for rubella (rubella titer was negative). M-M-R II was administered on-29-APR-1996 and 30-AUG-1999. Each dose was given 0.5 ml intramuscularly. Confirmed that doses of M-M-R II were given intramuscularly. No treatment was given for the adverse events. The outcome of the events was unknown. Causality assessment was not provided. No product quality complaint (PQC) was involved. No further information provided. This is one of two reports received from the same reporter. Additional information has been requested.
Patient broke out on hives all over her body.  It was very itchy.  She calmed down after a dose of Zyrtec, but the hives come back after the meds wear off.  Patient has never had hives before.
Employee rec'd influenza vaccine in (L) Deltoid, that evening developed stiff shoulder and couldn't move arm. Three weeks later and still having pain and stiffness in shoulder at injection site.
on 8/18 pt. reports left back leg pain, very sore and blisters. on 08/19 she went to walk-in clinic and was given oral & topical antibiotics. on 08/20 she received the Shingrix vaccine.  Her symptoms progressed to more wide spread pain. on 08/24 she saw another MD and was diagnosed with shingles.
A few days after getting the second dose of Pfizer's COVID vaccine, I had some dizziness, palpitations, and a full-body rash. I went to an urgent care facility who called the ambulance for me as my heart rate skyrocketed to 200 bpm. I was given medication to restart my heart twice en route to the ER (same place I got the shot) and there I was admitted for a day. I was there over night and left the following afternoon with medication to keep my heart rate down, as well as some anti-inflammatory drugs. I was told not to report it to VAERS because they believed it could not be vaccine-related. Since then, I have been through a lot of doctor's visits, cardiologists, constant heart monitoring, and a lot of anxiety that such an event will happen again. After contacting the CDC in light of the recent studies showing heart issues in young people who got the shot, I was told that it was definitely reportable, so I am only just now writing about it.
Chills, cough, wheezing, redness at injection site (about 1 1/2 inches around injection site), couldn't lift arm. Reactions were more severe with the second dose than with the first dose.
It gave me/Suspected vaccination failure; It gave me; burns you inside; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: It gave me/Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: It gave me) and burning sensation (Verbatim: burns you inside). The outcome of the vaccination failure was unknown and the outcome of the shingles and burning sensation were not reported.   It was unknown if the reporter considered the vaccination failure, shingles and burning sensation to be related to Shingles vaccine.   It was unknown if the company considered the vaccination failure, shingles and burning sensation to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 12-MAR-2023 This case was reported by a patient via interactive digital media. The reporter stated that there were two types of shingles vaccines for that. The reporter further stated that it gave him/her shingles but he/she was already got vaccinated with shingles , that burned you inside.  This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow up would not possible as no contact details were available.
Tinnitus which began within a few days of dose 2.  It has not subsided and is getting worse.  It is now affecting my hearing .  This effects my occupation as I am a registered nurse and have to use a stethoscope daily in my job.  I am experiencing hearing loss which is making it difficult to hear with the stethoscope and the ringing in my ears never stops.
Raised, red lump on arm at injection site.  Measures approx. 4" in length by 2" in width.
pt recv vax & devel angioedema on the skin creases of the legs; Md planned to send the pt to dermatologist; f/u from MD 15NOV94 indicates pt had rxn to chemical on car seat, not vax
red raised pin point skin rash with puritis. upper torso front and back. treated with benadryl and zyrtec and cortisone cream
Continuous metallic (almost burning), acrid taste in mouth/tongue, noted 24 hours approx after injection to current date.  Burning sensation in eyes intermittently.   No other issues noted.  No fever recorded.  No treatment sought.
they accidentally administered a dose of the Moderna COVID-19 Vaccine Bivalent booster instead of a dose of the primary series; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (they accidentally administered a dose of the Moderna COVID-19 Vaccine Bivalent booster instead of a dose of the primary series) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (they accidentally administered a dose of the Moderna COVID-19 Vaccine Bivalent booster instead of a dose of the primary series) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (they accidentally administered a dose of the Moderna COVID-19 Vaccine Bivalent booster instead of a dose of the primary series) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (they accidentally administered a dose of the Moderna COVID-19 Vaccine Bivalent booster instead of a dose of the primary series).    Concomitant medication was not reported. It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  HCP stated that they accidentally administered a dose of the Moderna COVID-19 vaccine Bivalent booster instead of a dose of the primary series. It was unknown if patient reported any AE, or if there was any treatment given.   Reporter did not allow further contact
Syncope. Had pt. lay on the floor. Pt. recovered. No injury or other treatment needed.
8 days after the 1st Moderna Covid 19 vaccine the injection site on my left arm was red, swollen, and warm to the touch. It also hurt under my arm pit on that day and a few days prior to seeing the rash.  Directly following the vaccine (hours after until 3 days after) my arm was very sore and it was uncomfortable to move it. Those symptoms went away and I thought I was done with the side effects. Then that rash appeared 8 days later as stated above.